中药上市后临床再评价样本含量估算  

Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine

作　　者：付莹坤[1] 谢雁鸣[1] 

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700

出　　处：《中国中药杂志》2011年第20期2904-2906,共3页China Journal of Chinese Materia Medica

基　　金：国家"重大新药创制"科技重大专项(2009ZX09502-030);中国中医科学院自主选题研究项目(Z0133)

摘　　要：近年来,随着国家对中药(中成药)上市后再评价的关注,部分中药品种已经或即将开展上市后的临床再评价研究。为保证再评价结果起着一定的准确度和可靠性,达到预期把握度,样本量确定在临床试验设计中起着决定性作用。至今还未有针对中药上市后临床再评价研究样本含量计算的系统方法,该文根据临床研究样本量确定的基本方法结合中药上市后临床再评价的特点,分别探讨了中药有效性及安全性再评价中样本量的确定方法,为中药上市后临床再评价样本含量的估算提供参考。In recent years, as the Chinese government and people pay more attention on the post-marketing research of Chinese Medicine, part of traditional Chinese medicine breed has or is about to begin after the listing of post-marketing evaluation study. In the post-marketing evaluation design, sample size calculation plays a decisive role. It not only ensures the accuracy and reliability of postmarketing evaluation, but also assures that the intended trials will have a desired power for correctly detecting a clinically meaningful difference of different medicine under study if such a difference truly exists. Up to now, there is no systemic method of sample size calculation in view of the traditional Chinese medicine. In this paper, according to the basic method of sample size calculation and the characteristic of the traditional Chinese medicine clinical evaluation, the sample size calculation methods of the Chinese medicine efficacy and safety are discussed respectively. We hope the paper would be beneficial to medical researchers, and pharmaceutical scientists who are engaged in the areas of Chinese medicine research

关 键 词：中药 上市后 临床评价 样本量 

分 类 号：R28[医药卫生—中药学] F426.72[医药卫生—中医学]